达格列净在2型糖尿病女性与男性中的疗效与安全性
DECLARE-TIMI 58试验预设分析显示,达格列净在2型糖尿病女性与男性中降低心血管死亡或心衰住院、肾脏复合结局的风险相似,且安全性相当;女性基线HbA1c更高、糖尿病病程更长、降糖药使用更少。
要点
- 达格列净对心血管死亡或心衰住院的获益无性别差异(交互P=0.90)。
- 肾脏复合结局风险降低女性HR 0.50、男性HR 0.55,交互P=0.64。
- MACE风险降低无性别差异(交互P=0.99),安全性特征相似。
核心结论
- 达格列净在女性和男性中提供相似的心血管和肾脏获益及安全性。
研究设计与样本
- DECLARE-TIMI 58随机对照试验预设分析,纳入17,160例2型糖尿病伴动脉粥样硬化疾病或风险患者,中位随访4.2年。
主要发现
- 女性(n=6422,37.4%)基线HbA1c更高、糖尿病病程更长、降糖药物使用更少。
- 心血管死亡或心衰住院:女性3.8% vs 4.5%(HR 0.84,95%CI 0.66-1.07),男性5.3% vs 6.4%(HR 0.83,95%CI 0.71-0.96),交互P=0.90。
- MACE:女性6.3% vs 6.8%(HR 0.93,95%CI 0.77-1.12),男性10.0% vs 10.7%(HR 0.93,95%CI 0.83-1.05),交互P=0.99。
- 肾脏复合结局:女性1.4% vs 2.8%(HR 0.50,95%CI 0.35-0.70),男性1.5% vs 2.5%(HR 0.55,95%CI 0.42-0.73),交互P=0.64。
关键数值与推荐
- 心血管死亡或心衰住院、MACE、肾脏复合结局(eGFR持续下降≥40%至<60 ml min-1 [1.73 m]-2、终末期肾病或肾死亡)的HR及交互P值如上。
临床怎么用
- 达格列净用于2型糖尿病女性与男性患者时,心血管和肾脏获益及安全性相似,无需因性别调整预期。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of CV death or heart failure hospitalisations in individuals with type 2 diabetes. Here, we performed a pre-specified analysis to examine whether sex modifies these effects. METHODS: The DECLARE-TIMI 58 trial randomised 17,160 patients with type 2 diabetes with or at risk for atherosclerotic disease to dapagliflozin or placebo (median follow-up 4.2 years). The dual efficacy outcomes were CV death or heart failure hospitalisations, and major adverse cardiovascular events (MACE; CV death, myocardial infarction or ischaemic stroke). The renal-specific composite outcome was a sustained ≥40% drop in eGFR to <60 ml min-1 [1.73 m]-2, new end-stage renal disease or renal death. Cox models were run separately by sex with treatment-by-sex interaction testing for each outcome. RESULTS: At baseline, women (n = 6422, 37.4%) had higher HbA1c, longer type 2 diabetes duration, and were on fewer glucose-lowering medications. There was no evidence of modification of the effect of dapagliflozin by sex for (1) CV death or heart failure hospitalisations: women (3.8% vs 4.5%; HR 0.84, 95% CI 0.66, 1.07) and men (5.3% vs 6.4%; HR 0.83, 95% CI 0.71, 0.96; pinteraction = 0.90); (2) MACE: women (6.3% vs 6.8%; HR 0.93, 95% CI 0.77, 1.12) and men (10.0% vs 10.7%; HR 0.93, 95% CI 0.83, 1.05; pinteraction = 0.99); or (3) renal-specific composite: women (1.4% vs 2.8%; HR 0.50, 95% CI 0.35, 0.70) and men (1.5% vs 2.5%; HR 0.55, 95% CI 0.42, 0.73; pinteraction = 0.64). The overall safety profile of dapagliflozin was similar for women and men. CONCLUSIONS/INTERPRETATION: Dapagliflozin offers comparable CV and renal benefits and a comparable safety profile in women and men. FUNDING: AstraZeneca. TRIAL REGISTRATION: clinicaltrials.gov NCT01730534.
引用
- O'Donoghue ML, Kato ET, Mosenzon O, et al. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia. 2021. PMID: 33611623. doi:10.1007/s00125-021-05399-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。